Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Sep 27;8(10):1556. doi: 10.3390/jcm8101556

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Survival of the Erdman strain of Mycobacterium tuberculosis treated with Pyrazinamide and Isoniazid in media. (A) M. tb growth in 7H11 agar media from non-vaccinated subjects with liposomal glutathione (L-GSH) treatment along with Hematoxylin and Eosin (H&E) images of granuloma like structures from eight-day terminated samples; (B) M. tb growth in 7H11 agar media from Bacille Calmette–Guérin (BCG) vaccinated subjects with L-GSH treatment along with H&E images of granuloma-like structures from eight-day terminated samples; (C) M. tb growth in 7H11 agar media with pyrazinamide (PZA), 1/10 PZA, and 1/100 PZA treatment in the presence or absence of L-GSH in non-vaccinated subjects; (D) M. tb growth in 7H11 agar media with PZA, 1/10 PZA, and 1/100 PZA treatment in the presence or absence of L-GSH in BCG-vaccinated subjects. (E) M. tb growth in 7H11 agar media from non-vaccinated (white bar) and BCG-vaccinated (black bar) groups with sham treatment and L-GSH treatment; (F) M. tb growth in 7H11 agar media in non-vaccinated and BCG-vaccinated groups with PZA treatment. Data represents ± SE(standard error) rom experiments performed from 14 different subjects. An unpaired t-test with Welch corrections was used in Figure (A). Analysis of Figures B–F utilized a one-way ANOVA (analysis of variance) with Tukey test. The p value style consisted of 0.1234 as not significant, 0.0332 with one asterisk (*), 0.0021 with two asterisks (**), 0.0002 with three asterisks (***), and less than 0.0001 with four asterisks (****). A hash mark (#) indicates categories compared to control, and an asterisk indicates categories compared to the previous category directly before it. (G) M. tb growth in 7H11 agar media with isoniazid (INH), 1/10 INH, and 1/100 INH treatment in the presence or absence of L-GSH in non-vaccinated subject; (H) M. tb growth in 7H11 agar media with INH, 1/10 INH, and 1/100 INH treatment in the presence or absence of L-GSH in BCG-vaccinated subjects; (I) M. tb growth in 7H11 agar media in non-vaccinated and BCG-vaccinated groups with INH treatment. Data represents ± SE from experiments performed from 14 different subjects. Analysis of figures utilized a one-way ANOVA with Tukey test. The p value style consisted of 0.1234 as not significant, 0.0332 with one asterisk (*), 0.0021 with two asterisks (**), 0.0002 with three asterisks (***), and less than 0.0001 with four asterisks (****). A hash mark (#) indicates categories compared to control, and an asterisk indicates categories compared to the previous category directly before it.

Survival of the Erdman strain of Mycobacterium tuberculosis treated with Pyrazinamide and Isoniazid in media. (A) M. tb growth in 7H11 agar media from non-vaccinated subjects with liposomal glutathione (L-GSH) treatment along with Hematoxylin and Eosin (H&E) images of granuloma like structures from eight-day terminated samples; (B) M. tb growth in 7H11 agar media from Bacille Calmette–Guérin (BCG) vaccinated subjects with L-GSH treatment along with H&E images of granuloma-like structures from eight-day terminated samples; (C) M. tb growth in 7H11 agar media with pyrazinamide (PZA), 1/10 PZA, and 1/100 PZA treatment in the presence or absence of L-GSH in non-vaccinated subjects; (D) M. tb growth in 7H11 agar media with PZA, 1/10 PZA, and 1/100 PZA treatment in the presence or absence of L-GSH in BCG-vaccinated subjects. (E) M. tb growth in 7H11 agar media from non-vaccinated (white bar) and BCG-vaccinated (black bar) groups with sham treatment and L-GSH treatment; (F) M. tb growth in 7H11 agar media in non-vaccinated and BCG-vaccinated groups with PZA treatment. Data represents ± SE(standard error) rom experiments performed from 14 different subjects. An unpaired t-test with Welch corrections was used in Figure (A). Analysis of Figures B–F utilized a one-way ANOVA (analysis of variance) with Tukey test. The p value style consisted of 0.1234 as not significant, 0.0332 with one asterisk (*), 0.0021 with two asterisks (**), 0.0002 with three asterisks (***), and less than 0.0001 with four asterisks (****). A hash mark (#) indicates categories compared to control, and an asterisk indicates categories compared to the previous category directly before it. (G) M. tb growth in 7H11 agar media with isoniazid (INH), 1/10 INH, and 1/100 INH treatment in the presence or absence of L-GSH in non-vaccinated subject; (H) M. tb growth in 7H11 agar media with INH, 1/10 INH, and 1/100 INH treatment in the presence or absence of L-GSH in BCG-vaccinated subjects; (I) M. tb growth in 7H11 agar media in non-vaccinated and BCG-vaccinated groups with INH treatment. Data represents ± SE from experiments performed from 14 different subjects. Analysis of figures utilized a one-way ANOVA with Tukey test. The p value style consisted of 0.1234 as not significant, 0.0332 with one asterisk (*), 0.0021 with two asterisks (**), 0.0002 with three asterisks (***), and less than 0.0001 with four asterisks (****). A hash mark (#) indicates categories compared to control, and an asterisk indicates categories compared to the previous category directly before it.